Ascensia and Voluntis to optimise insulin management for type 2 diabetes

11 June 2017 (Last Updated November 22nd, 2018 11:24)

Switzerland-based Ascensia Diabetes Care has entered a global technology partnership with French firm Voluntis to optimise insulin management for patients suffering from type 2 diabetes.

Switzerland-based Ascensia Diabetes Care has entered a global technology partnership with French firm Voluntis to optimise insulin management for patients suffering from type 2 diabetes.

Voluntis’ Insulia Diabetes Management Companion, a basal insulin management solution for type 2 diabetes, will be integrated with Ascensia’s Contour Next One and Contour Plus One blood glucose monitoring systems (BGMS).

Based on diabetes-related data such as blood glucose values, Insulia provides insulin dose recommendations and educational coaching messages via a smartphone app.

The Contour systems feature a blood glucose smart metre that is connected to a mobile app called Contour Diabetes.

Through Bluetooth, the app collects, stores and analyses patient blood glucose measurements that are delivered by the metres.

"The simplicity and effectiveness of the Insulia solution combined with the remarkable accuracy of the Contour Next One and Contour Plus One blood glucose monitoring systems, has the ability to meaningfully impact the lives of people living with diabetes."

Ascensia Diabetes Care CEO Michael Kloss said: "The simplicity and effectiveness of the Insulia solution combined with the remarkable accuracy of the Contour Next One and Contour Plus One blood glucose monitoring systems, has the ability to meaningfully impact the lives of people living with diabetes, and as a result, this could lead to better outcomes."

Basal insulin dosing for the patients will be calculated using the blood glucose readings obtained from the devices.

The primary objective of the integration is to enable self-management and insulin management optimisation for patients.

The connected solutions are expected to be available for diabetes patients and healthcare professionals in the fourth quarter of this year.

Ascensia has also signed a development agreement to connect its Contour Next One BGMS with Insulet's Omnipod Dash System that is currently being developed to enable diabetes management.